Posted in | News | Chemistry

Photosynthesis of Chiral Building Blocks for Drug Discovery

A new white paper, written by scientists at Liverpool ChiroChem (LCC), describes how the Asynt Illumin8 parallel photoreactor is being used to synthesise a range of new 2-Aryl N-Heterocycles.

Liverpool ChiroChem Logo


The discovery of a novel enantioselective synthetic pathway for reduction of pyridines to the corresponding chiral piperidines led to the formation of LCC in 2014. Since inception, LCC have enhanced their expertise enabling them to provide leading scientific organisations with access to chirally-pure compounds that play their part in small molecule drug discovery.

The white paper describes how using a combination of photoredox-mediated hydrogen atom transfer (HAT) and nickel catalysis - scientists were able to synthesise di- and tri-functionalised N-pyrrolidines of high interest to the drug discovery community.

Ross Goodyear, R&D chemist at Liverpool ChiroChem with the Illumin8 Parallel Photoreactor


Dr Shaun Smullen, a senior research chemist at LCC commented "Our initial photochemical reaction set-up using Kessil 40 W lamps was rather time consuming. The introduction of Asynt’s Illumin8 parallel photoreactor drastically improved our efficiency by allowing us to perform eight reactions simultaneously. The yields and selectivity of these reactions were comparable in both set-ups".

The Illumin8 parallel photoreactor is designed to be simple to set-up, flexible in operation and easy-to-use. It allows users to run up to eight photochemical reactions at a time in 6 mL borosilicate tubes. The unit mounts on a standard magnetic hotplate stirrer enabling powerful agitation and heating (up to 80 °C). Easy to use connectors, on top of the Illumin8, allow for an inert atmosphere or vacuum to be applied to each reaction tube. Compact in size, the Illumin8 parallel photoreactor features a ring of eight high power UV (365 nm) or blue (450 nm) light emitting diodes (LEDs) with safety interlocks to ensure light tight photochemical reactions. With each LED positioned close to a corresponding reaction tube, Illumin8 efficiently delivers an even photon flux to each reaction enhancing the consistency of your photochemical reactions.

 

Illumin8 Parallel Photoreactor


To read the LCC white paper in full please visit www.asynt.com/wp-content/uploads/2020/02/Photochemistry-with-Illumin8-LCC-white-paper-SHARE.pdf. For further information on the Illumin8 please visit https://www.asynt.com/product/illumin8-parallel-photoreactor/  or contact Asynt on +44-1638-781709 / [email protected].

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Asynt. (2021, May 19). Photosynthesis of Chiral Building Blocks for Drug Discovery. AZoM. Retrieved on April 26, 2024 from https://www.azom.com/news.aspx?newsID=56132.

  • MLA

    Asynt. "Photosynthesis of Chiral Building Blocks for Drug Discovery". AZoM. 26 April 2024. <https://www.azom.com/news.aspx?newsID=56132>.

  • Chicago

    Asynt. "Photosynthesis of Chiral Building Blocks for Drug Discovery". AZoM. https://www.azom.com/news.aspx?newsID=56132. (accessed April 26, 2024).

  • Harvard

    Asynt. 2021. Photosynthesis of Chiral Building Blocks for Drug Discovery. AZoM, viewed 26 April 2024, https://www.azom.com/news.aspx?newsID=56132.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.